SCHEMBL6979199

SCHEMBL6979199

CCOC(=O)c1cncc(C)c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 2/20 0.72
CYP2C9 P11712 1/20 0.72
ATM Q13315 1/20 0.68
HCAR2 Q8TDS4 1/20 0.58
CA12 O43570 3/20 0.52
CA1 P00915 3/20 0.52
CA2 P00918 3/20 0.52
CA7 P43166 3/20 0.52
CA9 Q16790 3/20 0.52
CA14 Q9ULX7 3/20 0.52
ESR1 P03372 1/20 0.47
ESR2 Q92731 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
ALDH1A1 P00352 1/20 0.47
MAPT P10636 1/20 0.47
CYP1A2 P05177 2/20 0.46
CYP3A4 P08684 2/20 0.46
LMNA P02545 1/20 0.46
MAOA P21397 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Oxirane SCHEMBL28902733 0.92 CYP2C19 (0.62) CYP2C19CYP2C9ATMHCAR2CA12
SCHEMBL277284 0.90 CYP2C19 (0.86) CYP2C19CYP2C9ATMCA12CA1
Hydrochloric Acid SCHEMBL9679507 0.89 CYP2C19 (0.83) CYP2C19CYP2C9ATMCA12CA1
SCHEMBL12678033 0.88 ATM (0.62) CYP2C19CYP2C9ATMHCAR2CA12
SCHEMBL18132197 0.86 ATM (0.64) CYP2C19CYP2C9ATMHCAR2CA12
SCHEMBL18132271 0.86 ATM (0.64) CYP2C19CYP2C9ATMHCAR2CA12
SCHEMBL19556182 0.84 CYP2C19 (0.66) CYP2C19CYP2C9ATMCA12CA1
SCHEMBL20298339 0.84 ATM (0.57) CYP2C19CYP2C9ATMHCAR2CA12
SCHEMBL12629121 0.84 CYP2C19 (0.70) CYP2C19CYP2C9ATMCA12CA1
SCHEMBL1812268 0.84 CYP2C9 (0.70) CYP2C19CYP2C9ATMCA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023061263-A1 SHP2 INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF 北京泰德制药股份有限公司 2023-04-20 WO disclosed
CN-111662554-B Polyacetal composition and preparation method and application thereof 万华化学集团股份有限公司 2022-03-11 CN disclosed
EP-3778045-A1 COMPOUND FOR RESTORING CONTAMINATED SOIL OR CONTAMINATED WATER FNG Research Co., Ltd. (KR) 2021-02-17 EP disclosed
CN-111662554-A Polyacetal composition and preparation method and application thereof 万华化学集团股份有限公司 2020-09-15 CN disclosed
US-10383863-B2 Compounds and compositions for inducing chondrogenesis NOVARTIS AG (CH) 2019-08-20 US disclosed
EP-3188732-B1 TETRAHYDROISOQUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 MERCK SHARP & DOHME (US) 2019-07-24 EP disclosed
US-10188638-B2 Compounds and compositions for inducing chondrogenesis NOVARTIS AG (CH) 2019-01-29 US disclosed
US-9949979-B2 Use of inhibitors of the activity or function of PI3K NOVARTIS AG (CH) 2018-04-24 US disclosed
US-20170273965-A1 TETRAHYDROISOQUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 MERCK SHARP & DOHME CORP. (US) 2017-09-28 US disclosed
CN-105384738-B Heterocycle compound as kinases inhibitor and its production and use 上海科州药物研发有限公司 2017-08-29 CN disclosed
WO-2008006583-A1 PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS NOVARTIS AG (CH) 2008-01-17 WO disclosed
WO-2007095753-A1 2-(PHENYL OR HETEROCYCLIC) - 1H-PHENANTHRO [9,10-D] IMIDAZOLES MERCK FROSST CANADA LTD. (CA) 2007-08-30 WO disclosed
EP-0985671-B1 PYRIDOCARBAZOLE DERIVATIVES HAVING cGMP-PDE INHIBITORY EFFECT MOCHIDA PHARM CO LTD (JP) 2003-04-02 EP disclosed
US-6476021-B1 Compounds having cGMP-PDE inhibitory effect MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2002-11-05 US disclosed
US-6197768-B1 THERAPY, PREVENTION ISCHEMIC HEART DISEASE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2001-03-06 US disclosed
CN-1284075-A Novel compounds having CGMP-PDE inhibitory effect MOCHIDA PHARM CO LTD (JP) 2001-02-14 CN disclosed
EP-1048666-A1 NOVEL COMPOUNDS HAVING cGMP-PDE INHIBITORY EFFECT MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2000-11-02 EP disclosed
EP-0992240-A1 THERAPEUTIC AGENT FOR ERECTION FAILURE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2000-04-12 EP disclosed
EP-0985671-A1 PYRIDOCARBAZOLE DERIVATIVES HAVING cGMP-PDE INHIBITORY EFFECT MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2000-03-15 EP disclosed
US-6018046-A SELECTIVE ACTION IN INHIBITING CYCLIC GMP-PHOSPHODIESTERASE (CGMP-PDE); PHARMACEUTICALS FOR TREATING DISEASES AGAINST WHICH THE INHIBITORY ACTION IS EFFECTIVE, SUCH AS PULMONARY HYPERTENSION MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2000-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170273965-A1 TETRAHYDROISOQUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 DGAT2, DGAT1, MOGAT2 CYP2C19 1196/4885CYP2C9 1055/4885ATM 4183/4885
US-10188638-B2 Compounds and compositions for inducing chondrogenesis FGF1, COL2A1, FGFR3 CYP2C19 4493/4885CYP2C9 3926/4885ATM 2932/4885
US-10383863-B2 Compounds and compositions for inducing chondrogenesis FGF1, COL2A1, FGFR3 CYP2C19 4493/4885CYP2C9 3926/4885ATM 2932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.